Biochemical Pharmacology volume 77, issue 3, P297-309 2009 DOI: 10.1016/j.bcp.2008.10.033 View full text
Cinzia Lanzi, Giuliana Cassinelli, Valentina Nicolini, Franco Zunino

Abstract: The limited efficacy of conventional treatments in progressive thyroid carcinomas indicates the need for new therapeutic options. Activating mutations of the receptor tyrosine kinase-encoding RET gene have been identified as driving oncogenic events in subsets of papillary (PTC) and medullary (MTC) thyroid carcinomas suggesting the interest of targeted therapy. The role of RET oncogenes and the encoded constitutively active oncoproteins as potential targets has been investigated by different strategies includi…

expand abstract